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Abstract
Background: Almost all researchers agree on the lack of Bob-1 expression in Hodgkin/Reed-
Sternberg (H/RS) cells in classic Hodgkin lymphoma (CHL), and utilize this marker as a diagnostic
tool in conjunction with other markers to differentiate between lymphocyte predominance
Hodgkin lymphoma (LPHL) and CHL.
Aim: To study the immunohistochemical (IHC) expression of Bob-1 in Egyptian CHL and to
correlate this expression with Epstein-Barr virus (EBV) viral load.
Materials and methods: Paraffin sections of randomly selected 18 CHL cases were included: 2
lymphocyte rich (LR), 4 mixed cellularity (MC), 10 nodular sclerosis (NS) and 2 lymphocyte
depletion (LD). All cases were immunostained for Bob-1. EBV was evaluated by EBV early RNA
transcripts in situ hybridization (EBER ISH) and immunostaining for EBV latent membrane protein-
1 (LMP-1).
Results: Sixty seven percent of cases (12/18) were positive for EBV by ISH and/or immunostaining
for LMP-1. Moderate to strong nuclear Bob-1 was observed in 94% of cases. The positivity ranged
between 25–100%. Bob-1 immunoreactivity was strongly associated with EBV positivity (p < 0.001).
Conclusion: This study proves nuclear IHC expression of Bob-1 on H/RS in CHL implying the
difficulties in applying this marker to differentiate between LPHL and CHL. Does this difference
between Western and Egyptian CHL reflect genetic and/or environmental factors, or simply no
difference exists as most researchers are concentrated on the Western population and no
comparative studies have been done. Studies from other countries might answer this question.
Background
According to the World Health Organization (WHO) clas-
sification of haematological malignancies [1], the B-cell
specific transcriptional co-activator or Bob-1/OCA-B is
not expressed on H/RS cells, a point used to differentiate
between CHL and LPHL, the latter being Bob-1 positive.
Bob-1/OCA-B located on chromosome 11q23.1 [2], is
involved in the transcription of immunoglobulin (Ig)
genes through recruitment of the highly conserved
octamer site of Ig promoters, mediated by either Oct-1 or
Oct-2 transcription factor [3]. Bob-1 is essential for the
response of B cells to antigens, and is required for the for-
mation of the germinal centre (GC) [4].
EBV, the main etiologic agent for HL [5], has been
reported in 30–50% of cases in developed countries and
in up to 95% of cases in developing ones [6]. The detec-
tion of EBV in H/RS cells is mainly based on the detection
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of EBV early RNA transcripts (EBER) [7].
As H/RS cells originate from the GC [8-10], they are
expected to express B cell markers such as Bob-1. There-
fore this work was undertaken to study the expression of
Bob-1 in Egyptian CHL and to correlate this expression
with EBV viral load in an attempt to find out if differences
do exist between Western and Egyptian CHL, for optimal
assessment of the treatment regime.
Materials and methods
Classic Hodgkin lymphoma cases
Paraffin sections of randomly selected CHL were classified
according to the WHO [1]. A total of 18 CHL cases were
studied. These included 2 cases of LRHL, 4 MCHL, 10
NSHL, 2 LDHL. The positive controls consisted of 2 reac-
tive nodes selected with follicular hyperplasia and 2 cases
of LPHL. The initial diagnostic panel included CD30,
CD15, CD20 and CD3. EMA and ALK-1 were performed
whenever indicated to rule out LPHL and anaplastic large
cell lymphoma.
Immunohistochemistry
The expression of Bob-1 and EBV LMP-1 was evaluated by
immunostaining (table 1). Following deparaffinization,
endogenous peroxidase was inhibited by tissue sections
incubation for 10 minutes at room temperature in 0.3%
H2O2. Following antigen retrieval, slides were rinsed in
distilled water and finally phosphate buffered saline
(PBS). All incubations were performed at room tempera-
ture. After incubation with the primary antibody, sections
were rinsed in PBS and incubated with the LSAB-2 detec-
tion kit and the steps were followed according to the man-
ufacturer instructions (Dakocytomation).
Diaminobenzedine tetrachloride (DAB) was applied for
10 minutes and lastly, sections were counterstained with
Harris haematoxylin (Hx).
Evaluation of immunohistochemical staining
The percentage of positively stained H/RS cells were semi-
quantitatively determined as follows: 0- absence or stain-
ing of less than 5% of H/RS cells; +) 5–25%; ++) > 25–
50%; +++) > 50–75%; ++++) > 75% of H/RS cells showed
a positive staining. In all cases, small reactive lymphocytes
served as positive internal control for Bob-1, in addition
to the positivity of the reactive nodes and lymphocytic/
histiocytic cells of LPHL.
In-situ hybridization
The ISH steps were performed according to the manufac-
turer's instructions (Novocastra, NCL-EBV-K). The slides
were first dewaxed in xylene, hydrated in descending
grades of alcohol and lastly immersed in water. One hun-
dred µl of proteinase K in 0.05 mM Tris/HCL buffer pH
7.6 were applied for 10 minutes at 37°C. This step was fol-
lowed by slides immersion in water, dehydration and air
drying. Depending on the tissue section, 20 to 50 µl of the
probe hybridization solution were applied. Sections were
coverslipped and incubated for 2 hours at 37°C. The cov-
ers were allowed to drain off into a beaker; they were then
washed in Tris containing 0.1% triton X-100. For the
detection, 100 µl of the blocking solution was applied for
10 minutes followed by rabbit F (ab') anti-FTTC conju-
gated to alkaline phosphatase (AP) diluted 1:100 for 30
minutes. Slides were subsequently washed in TBS fol-
lowed by the AP substrate buffer. The AP activity was dem-
onstrated by incubation in dark overnight with a mixture
solution of 5 bromo-4 choro indolyl phosphate, nitro-
blue tretrazolium (BCNT). Finally, the slides were washed
and counterstained with Mayer's haematoxylin. The con-
trol of the procedure included positive control sections
and negative control probe supplied with the ISH kit.
Evaluation of in-situ hybridisation
The staining was considered positive when dark blue to
black dots were encountered in the nuclei of the H/RS
cells together with positivity of the positive control tissue
and negativity of the duplicate sections hybridized with
the negative probe.
Statistical analysis
The association between Bob-1 positive cells and EBV
viral load was evaluated using the Chi square test.
Results
In reactive nodes, residual follicles and inflammatory
milieu of HL, strong nuclear Bob-1 was expressed in GC B
Table 1: Reagents used for IHC in the study
Bob-1 LMP-1
Source Santa Cruz Dakocytomation
Reference Sc 955 rabbit polyclonal M0897, monoclonal
Heat induced epitope retrieval Citrate pH 6.0, 750 w × 5 m × 3 times
Dilution 1:1500 1:50
Incubation 60 m 30 m
Interpretation Nuclear Membranous, cytoplasmic and/or paranuclear dotPage 2 of 5
(page number not for citation purposes)
Diagnostic Pathology 2007, 2:10 http://www.diagnosticpathology.org/content/2/1/10cells while moderate staining was seen in scattered mantle
zone B cells and interfollicular T cells.
In CHL, moderate to strong nuclear IHC Bob-1+ H/RS
cells were encountered in 94% of cases irrespective of the
subtype. The percentage of positive cells ranged from 25–
100% (table 2, figures 1, 2, 3). Membranous, cytoplasmic
and/or paranuclear dot staining for LMP-1 (figure 4) was
identified in 61%, while nuclear staining for EBER-ISH
(figure 5) was encountered in 67% of cases. A close asso-
ciation was found between Bob-1 immunoreactivity and
EBV viral load (p < 0.001).
Discussion
CHD is a B-cell neoplasm in nearly all instances derived
from the GC B cells harbouring somatically mutated IgV
region genes. However, these cells have consistently lost
their Ig gene transcription ability, due to functional
defects in the Ig gene regulatory elements [10-12]. The
defect has been attributed to crippling mutations [11,12],
a defect in the transcription machinery due to lack of
expression of the octamer transcription factor Oct2 and/
or its coactivator Bob-1 [12,14], or epigenetic silencing in
the inhibition of IgH transcription [15].
The expression of Bob-1 in H/RS cells was a surprising
finding. To our knowledge, this is the first study reporting
strong nuclear Bob-1 in almost all H/RS cells. In reactive
nodes and non neoplastic cells in HL, Bob-1 IHC expres-
sion is concordant with the literature [16,17]. However, in
neoplastic conditions, Bob-1 positivity is restricted to
LPHL and has been a useful tool in differentiating it from
CHL [13,18-20]. Only one previous study using tissue
microarray, reported Bob-1+ H/RS cells in 17% of cases
with strong Bob-1 positivity in only 2% of cases [21].
Should the strong IHC expression of Bob-1 in H/RS cells
is really to be an unexpected finding? First, in HL cell lines,
Oct-2 has been reported in one study to be constantly
expressed on H/RS cells [22]. Second, a close resemblance
has been found between primary mediastinal B-cell lym-
phoma (PMBL) and CHL [23-25]. PMBL signature genes
revealed an extraordinarily robust gene expression rela-
tionship between PMBL and HL, strongly supporting a
pathogenetic relationship between these two lymphoma
types [24,25]. On IHC basis, PMBL are PAX5/BSAP+, Bob-
1+, Oct-2+, PU.1+, Bcl-2+, CD30+, HLA-DR+, Bcl-6+/-,
Mum-1+/- [26], markers already identified on CHL with
the exception of PU.1, Bob-1 and Oct-2 [13,19,28,27]. In
addition, the MAL protein initially a PMBL marker [29],
has been identified on H/RS cells from a case of NSHL in
the study of Rosenwald et al [24]. Furthermore, PMBL and
HL have rearranged Ig genes but lack surface Ig [10,11,24].
Considering these previous findings together with the
results of our research, one can conclude that the expres-
MCHL: strong nuclear Bob-1 staining in all H/RS cells, Bob-1 immuno aining, DAB, Hx, × 40Figure 2
MCHL: strong nuclear Bob-1 staining in all H/RS cells, Bob-1 
immunostaining, DAB, Hx, × 40.
Table 2: Bob-1 and EBV expressions in CHL
CHL Subtype Bob-1 EBV viral load
EBER LMP-1
LRHL 2/2 2/2 1/2
MC 4/4 3/4 3/4
NS 9/10 6/10 6/10
LD 2/2 1/2 1/2
Total 17/18 12/18 11/18
% 94% 67% 61%
MCHL H/RS cells in an inflammatory background, H&E × 40Figure 1
MCHL H/RS cells in an inflammatory background, H&E × 40.Page 3 of 5
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uncommon finding.
What could be the other explanations of Bob-1+H/RS cells
in the present study? It has been speculated that EBV con-
tributes to the transformation and maintenance of H/RS
cells, by rescuing them from apoptosis. This has been
attributed to the oncogenic potential of LMP-1 on B cells
through upregulation of anti-apoptosis genes including
bcl-2 [30], downregulation of p16INK4a [31] and activa-
tion of NFκB [32]. What is the relation between EBV and
Bob-1? NFκB and Bob-1 are transcription factors required
for mouse B cell differentiation, serum IgM production,
late B cell maturation and function [33]. It seems that the
activation of NFκB in EBV positive cases is associated with
up regulation of Bob-1 since there is a close association
between the expression of Bob-1 and EBV in the present
study.
In conclusion, this study confirms the nuclear expression
of Bob-1 on H/RS cells in CHL, making the utility of Bob-
1 to differentiate between LPHL and CHL difficult. These
points open questions concerning environmental factors
especially early EBV infection in developing countries and
to lesser extent genetic ones. Is there truly a difference
between Western and Egyptian CHL, or no differences
actually exist as most researchers are more concentrated
on their own Western-based populations? We feel that our
work necessitates cooperative studies between different
countries to answer these questions.
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